Patent News Release Toronto, Ontario – TheNewswire – August 09, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has filed an international patent application under the Patent Cooperation Treaty (PCT) to protect Ventripoint’s recent novel improvements to its cardiac measurement technology. Ventripoint is a pioneer in application of artificial intelligence (AI) to heart analysis and this latest application strengthens the company’s intellectual property position and coverage for the Ventripoint’s flagship products. With this one international patent application, Ventripoint registers its claim to this invention in at least 153 different contracting countries under the PCT.
Dr. George Adams, CEO of Ventripoint, stated, “The filing of this latest patent application along with previous patent applications and licenses builds a strong intellectual property (IP) estate. Technology companies are valued for their IP and Ventripoint continues to pioneer novel ways to apply AI to cardiac analysis for the betterment of patients, especially children, worldwide.”
The patent application has been filed under the invention title “System, Method, and/or Computer-Readable Medium for Mapping and Displaying Anatomical Structures in a User-Friendly Manner”. It claims a new, improved method of using 2D and 3D echocardiography data for mapping and displaying the anatomical structure and configuration of the heart. A key novel component is the use of templates with predetermined anatomical landmarks so that multiple anatomical features of the heart are aligned simultaneously.
This upgrade to Ventripoint’s VMS+ products shortens the analysis time for both 2D and 3D echocardiograms and will help clinicians obtain more accurate and reliable results. The patent relates to the method of using 2D and 3D echocardiography data for mapping and displaying the anatomical structure of the heart for all four pumping chambers of the heart.
Cardiovascular diseases continue to be the largest cause of death worldwide. Providing clinicians with the latest advancements in diagnostic tools will play a pivotal role in combating cardiovascular disease and sustaining robust hearts.